- Investing.com
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Metrics to compare | REG1V | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREG1VPeersSector | |
---|---|---|---|---|
P/E Ratio | 38.9x | 25.2x | −0.5x | |
PEG Ratio | 15.41 | 0.78 | 0.00 | |
Price/Book | 6.6x | 2.5x | 2.6x | |
Price / LTM Sales | 7.0x | 1.5x | 3.1x | |
Upside (Analyst Target) | 9.0% | 11.0% | 48.6% | |
Fair Value Upside | Unlock | 15.6% | 8.9% | Unlock |